Alexandra Gerlach, Content Producer

The most substantial reduction was achieved 2 to 3 years after vaccination with a sustained protective effect lasting up to 8 years.

The fixed-dose combination yielded a 49% greater reduction in low density lipoprotein cholesterol (LDL-C) compared with placebo.

The agent demonstrated promising tolerability and manageable safety.

Trastuzumab deruxtecan was safe and efficacious prior to treatment with paclitaxel, trastuzumab, and pertuzumab.

Adherence to GLP-1 receptor agonists showed a 59% drop in inpatient hospital costs.

Patients with myelofibrosis who stopped ruxolitinib on the first day of conditioning did not show higher rates of acute graft-vs-host disease (GVHD).

The agent targets B7-H3, a commonly overexpressed protein in diffuse intrinsic pontine glioma (DIPG).

There was no significant increase in severe adverse events associated with statin use.

One dose of the vaccine compared with 2 may help increase global HPV vaccine uptake.

This installment of our series on ADCs and HER2 breast cancer offers key insights about novel agents in clinical trials and management of ADC therapies.

The salvage therapy led to an 80% overall response rate in patients with relapsed/refractory multiple myeloma.

Despite benefits for reducing drug costs, community oncology practices face the unintended consequences of the IRA.

Pharmacists are on the front lines of the outbreak, making them well-positioned to educate and counsel patients with vaccine hesitancy.

A survey showed that 92% of Americans are open to treatments that would slow disease progression.

Douglas Adkins, MD shares key data and findings from the phase 3 KEYNOTE-689 study.

Explore the role of JAK inhibitors in myelofibrosis treatment, focusing on optimizing dosages and managing adverse effects for better patient outcomes.

Biomarker testing transforms non-small cell lung cancer treatment, enhancing outcomes through targeted therapies and next-generation sequencing for better patient care.

Artificial intelligence (AI) models enhance cancer cachexia detection, improving accuracy in predicting muscle atrophy and patient outcomes through advanced biomarker analysis.

Explore the latest advancements in chronic lymphocytic leukemia treatment, focusing on BTK and BCL2 inhibitors, monoclonal antibodies, and patient management strategies.

Pharmacists discuss how drug design impacts drug efficacy and indications for HER2-low and -ultra-low breast cancer.

Hyperglycemia is a common and significant adverse effect of PI3K and AKT inhibitors in hormone receptor-positive (HR+) breast cancer.

Study shows a significant decline in breast cancer mortality across multiple subtypes.

Acneiform rash is a common adverse effect of EGFR-targeting therapies.

Dostarlimab in the neoadjuvant setting yielded a 100% clinical complete response in patients with rectal cancer.

The study found that 4 weeks was the ideal time point to test for cTDNA.

This alternative to IV infusion reduces patient treatment times and eases providers’ operational burdens.

Pyrotinib is a tyrosine kinase inhibitor that is independently developed in China.

The combination yielded superior progression-free (PFS) survival compared with standard of care.

Patients in both arms achieved statistically significant rates of compliance up to 97%.

PAK5 is a protein that drives resistance to trastuzumab emtansine in patients with HER2+ breast cancer.